Immunicon Corporation to Present at 2008 ASCO Annual Meeting
For dates and times of the presentations, please see http://www.asco.org/. Following the conference, the Immunicon presentations will be posted on Immunicon's Web site at http://www.immunicon.com.
Abstract Presentations will include:
Category: Breast Cancer--Local-Regional and Adjuvant Therapy
-- Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial. (Abstract No: 503)
-- Detection of circulating tumor cells in peripheral blood of patients who underwent lung cancer surgery. (Abstract No: 7564)
Category: Tumor Biology and Human Genetics
-- Detection of Bcl-2 and apoptosis in circulating tumor cells during treatment of metastatic breast cancer. (Abstract No: 11016)
-- Circulating tumor cells (CTCs) and endothelial cells (CECs) in malignant pleural mesothelioma (MPM) and primary lung cancer (LC). (Abstract No: 11019)
-- Circulating tumor cells (CTC): A reliable predictor of treatment efficacy in metastatic breast cancer (MBC). (Abstract No: 11018)
Category: Lung Cancer--Metastatic Lung Cancer
-- Characterization of NSCLC patients responding to anti-IGF-IR therapy. (Abstract No: 8000)
-- Circulating tumor cell analysis in patients with non-small cell lung cancer. (Abstract No: 19026)
Category: Genitourinary Cancer
-- Longitudinal analysis of circulating tumor cell (CTC) counts in prostate cancer patients: assessment of treatment efficacy. (Abstract No: 5169)
-- Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience. (Abstract No: 5072)
-- Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. (Abstract No: 5019)
-- Circulating tumor cells in patients with metastatic urothelial cancer. (Abstract No: 16054)
Category: Developmental Therapeutics: Molecular Therapeutics
-- Phase I open-labeled trial of gemcitabine and dasatinib in advanced solid tumors. (Abstract No: 14626)
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility and future promise of Immunicon's products and research and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon's ability to continue as a going concern; Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company; the risks and uncertainties with the arbitration proceeding with Veridex and the award in favor of Veridex given Immunicon's dependencies on Veridex; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon's ability to obtain licenses from third parties to commercialize products; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors' products; protection of Immunicon's intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.
"Immunicon," "CellTracks" and the Immunicon Corporation logo are registered trademarks of Immunivest Corporation, a subsidiary of Immunicon Corporation. Repeat-Free is a trademark of Immunivest Corporation. Poseidon is a trademark of Kreatech Diagnostics. ALL RIGHTS RESERVED.
Byron D. Hewett
President and CEO
Senior Vice President
Posted: May 2008